Terlouw Dianne J, Courval Jeanne M, Kolczak Margarette S, Rosenberg Oren S, Oloo Aggrey J, Kager Piet A, Lal Altaf A, Nahlen Bernard L, ter Kuile Feiko O
Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.
J Infect Dis. 2003 Feb 1;187(3):467-76. doi: 10.1086/367705. Epub 2003 Jan 24.
This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria. The dose was based on age: one-quarter tablet was given to infants <1 year old, one-half tablet was given to 1-3-year-old children, and a full tablet was given to 4-year-old children. Only 23.5% received the internationally recommended target dose of 25/1.25 mg of SP per kg of body weight. SP intake in the previous 15-35 days (adjusted relative risk, 1.67; 95% confidence interval, 1.35-2.07) and low SP dose (<27.5/1.375 mg/kg) (adjusted relative risk, 1.58; 95% confidence interval, 1.17-2.13) explained 38% of parasitological treatment failures by day 7. Patients with recent SP intake are likely to have recrudescent infections and may need close follow-up if treated with SP or alternative treatment. Applying our weight-for-age data to 31 existing age-based SP dose recommendations predicted that 22 of them would result in underdosing of >25% of children <5 years. Many age-based dose recommendations need urgent revision, because SP is increasingly used as first-line treatment in sub-Saharan Africa.
本研究回顾性分析了影响磺胺多辛-乙胺嘧啶(SP)疗效的可修正决定因素,研究对象为1072名患有非复杂性疟疾的肯尼亚5岁以下儿童,共涉及2869次治疗。剂量根据年龄确定:1岁以下婴儿服用四分之一片,1至3岁儿童服用半片,4岁儿童服用整片。只有23.5%的儿童接受了国际推荐的目标剂量,即每公斤体重25/1.25毫克的SP。在治疗前15至35天内服用过SP(调整后的相对风险为1.67;95%置信区间为1.35至2.07)以及低剂量SP(<27.5/1.375毫克/千克)(调整后的相对风险为1.58;95%置信区间为1.17至2.13)可解释7天内38%的寄生虫学治疗失败情况。近期服用过SP的患者可能会出现复发感染,如果使用SP或替代疗法进行治疗,可能需要密切随访。将我们的年龄别体重数据应用于31项现有的基于年龄的SP剂量推荐中,预计其中22项会导致5岁以下儿童中超过25%的儿童用药剂量不足。许多基于年龄的剂量推荐需要紧急修订,因为SP在撒哈拉以南非洲越来越多地被用作一线治疗药物。